Show simple item record

dc.contributor.authorLillegraven, Siri
dc.contributor.authorGreenberg, Jeffrey D.
dc.contributor.authorReed, George W.
dc.contributor.authorSaunders, Katherine
dc.contributor.authorCurtis, Jeffrey R.
dc.contributor.authorHarrold, Leslie R.
dc.contributor.authorHochberg, Marc C.
dc.contributor.authorPappas, Dimitrios A.
dc.contributor.authorKremer, Joel M.
dc.contributor.authorSolomon, Daniel H.
dc.date2022-08-11T08:09:52.000
dc.date.accessioned2022-08-23T16:46:38Z
dc.date.available2022-08-23T16:46:38Z
dc.date.issued2019-01-23
dc.date.submitted2019-02-28
dc.identifier.citation<p>PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019. <a href="https://doi.org/10.1371/journal.pone.0210459">Link to article on publisher's site</a></p>
dc.identifier.issn1932-6203 (Linking)
dc.identifier.doi10.1371/journal.pone.0210459
dc.identifier.pmid30673733
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40919
dc.description.abstractOBJECTIVE: Inflammation and anti-inflammatory treatments might influence the risk of diabetes. The objective of this study was to assess factors associated with incident diabetes in rheumatoid arthritis (RA). METHODS: The study population consisted of RA patients from a multi-center cohort study, Corrona. To assess risk associated with disease modifying antirheumatic drug (DMARD) exposure, we assessed five mutually exclusive DMARD groups. Additionally, we assessed the risk associated with body mass index (BMI, < 25, 25-30, > 30 kg/m2) and glucocorticoid usage. Incident cases of diabetes were confirmed through adjudication, and Cox regression models were fit to estimate the risk of incident diabetes. RESULTS: We identified 21,775 DMARD treatment regimens, the mean (SD) age at the index visit was 58 (13) years, disease duration 10 (10) years, and 30% used oral glucocorticoids at the time. Eighty-four incident cases of diabetes were confirmed within the treatment exposure periods. The hazard ratio (HR, 95% confidence interval) for diabetes was significantly reduced in patients receiving TNF inhibitors, HR 0.35 (0.13, 0.91), compared to patients treated with non-biologic DMARDs other than hydroxychloroquine and methotrexate. Hydroxychloroquine, methotrexate and use of other biologic DMARDs had a numerically reduced risk compared to the same group. Patients prescribed > /=7.5 mg of glucocorticoids had a HR of 2.33 (1.68, 3.22) of incident diabetes compared with patients not prescribed oral glucocorticoids. RA patients with a BMI > 30 had a HR of 6.27 (2.97, 13.25) compared to patients with BMI < /=25. CONCLUSION: DMARDs, glucocorticoids and obesity influenced the risk of incident diabetes in a large cohort of RA patients. Monitoring for the occurrence of diabetes should be part of routine RA management with a focus on specific subgroups.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=30673733&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright: © 2019 Lillegraven et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectDiabetes mellitus
dc.subjectRheumatoid arthritis
dc.subjectMethotrexate
dc.subjectBody mass index
dc.subjectObesity
dc.subjectDiabetes diagnosis and management
dc.subjectComparators
dc.subjectCytokines
dc.subjectEndocrine System Diseases
dc.subjectHormones, Hormone Substitutes, and Hormone Antagonists
dc.subjectImmune System Diseases
dc.subjectMusculoskeletal Diseases
dc.subjectNutritional and Metabolic Diseases
dc.subjectPathological Conditions, Signs and Symptoms
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.subjectTherapeutics
dc.titleImmunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
dc.typeJournal Article
dc.source.journaltitlePloS one
dc.source.volume14
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4731&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3719
dc.identifier.contextkey13921326
refterms.dateFOA2022-08-23T16:46:38Z
html.description.abstract<p>OBJECTIVE: Inflammation and anti-inflammatory treatments might influence the risk of diabetes. The objective of this study was to assess factors associated with incident diabetes in rheumatoid arthritis (RA).</p> <p>METHODS: The study population consisted of RA patients from a multi-center cohort study, Corrona. To assess risk associated with disease modifying antirheumatic drug (DMARD) exposure, we assessed five mutually exclusive DMARD groups. Additionally, we assessed the risk associated with body mass index (BMI, < 25, 25-30, > 30 kg/m2) and glucocorticoid usage. Incident cases of diabetes were confirmed through adjudication, and Cox regression models were fit to estimate the risk of incident diabetes.</p> <p>RESULTS: We identified 21,775 DMARD treatment regimens, the mean (SD) age at the index visit was 58 (13) years, disease duration 10 (10) years, and 30% used oral glucocorticoids at the time. Eighty-four incident cases of diabetes were confirmed within the treatment exposure periods. The hazard ratio (HR, 95% confidence interval) for diabetes was significantly reduced in patients receiving TNF inhibitors, HR 0.35 (0.13, 0.91), compared to patients treated with non-biologic DMARDs other than hydroxychloroquine and methotrexate. Hydroxychloroquine, methotrexate and use of other biologic DMARDs had a numerically reduced risk compared to the same group. Patients prescribed > /=7.5 mg of glucocorticoids had a HR of 2.33 (1.68, 3.22) of incident diabetes compared with patients not prescribed oral glucocorticoids. RA patients with a BMI > 30 had a HR of 6.27 (2.97, 13.25) compared to patients with BMI < /=25.</p> <p>CONCLUSION: DMARDs, glucocorticoids and obesity influenced the risk of incident diabetes in a large cohort of RA patients. Monitoring for the occurrence of diabetes should be part of routine RA management with a focus on specific subgroups.</p>
dc.identifier.submissionpathoapubs/3719
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.source.pagese0210459


Files in this item

Thumbnail
Name:
journal.pone.0210459.pdf
Size:
665.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright: © 2019 Lillegraven et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Except where otherwise noted, this item's license is described as Copyright: © 2019 Lillegraven et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.